🕒 Thursday 30 July 2026 Thu, 30 July 2026

Far East Gold has boosted its stake in the Idenburg Gold Project to 51%, revealing a 44% increase in inferred gold resources to 780,000 ounces. The company’s Independent Board Committee advises shareholders to reject an unsolicited takeover bid from Xingye Gold, which an expert deems undervalues the company.

Talga Group has marked a milestone with its first commercial delivery of natural graphite anode outside Asia, progressing key funding discussions and strategic partnerships to support its Vittangi Anode Project.

Tennant Minerals has confirmed robust high-grade copper-gold-bismuth mineralisation at its Bluebird discovery, extending the resource down-plunge and westward. The company secured $2.8 million in funding to accelerate drilling and development.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

The Supreme Court of New South Wales has approved Zurich’s acquisition of ClearView, setting a clear timetable for scheme implementation and shareholder payouts.

Livium Ltd has locked in A$1.575 million in initial funding from The Lind Partners, with potential to raise up to A$11.75 million over two years, while offering shareholders a discounted share purchase plan to support its recycling growth strategy.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.

Boab Metals has secured key contracts and financing milestones, accelerating the Sorby Hills Silver Lead Project with first production slated for H2 2027.

PTR Minerals has unveiled a substantial maiden Mineral Resource Estimate for its Rosewood Titanium Project, highlighting a large, high-grade heavy mineral deposit with strong metallurgical potential and strategic team expansions.

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.

Betr Entertainment reported its first positive operating cash flow since 2021 with $2.6 million in Q4 FY26, driven by improved customer engagement and promotional efficiency. The company enters FY27 with strong momentum, including over 15% turnover growth in July excluding World Cup effects and record Same Game Multi volumes.

Sunshine Metals has reported strong progress at its Queensland projects, highlighted by high-grade drilling results at Liontown, acquisition and planned upgrade of the Mt Moss processing facility, and a strategic divestment of Hodgkinson. The company bolsters its cash position through a $22 million capital raise to fund development and exploration.

Lac Gold Limited's latest drilling at the Rouyn Gold Project reveals extensive high-grade gold mineralisation, while the acquisition of the historic Golden Patricia Mine adds a significant growth platform. The company ends the quarter with $13.3 million in cash and a clear focus on resource expansion.

Brightstar Resources has greenlit full-scale construction of its Goldfields Project with all key approvals in place, targeting first gold in mid-2027 while boosting its Sandstone resource base to 2.9 million ounces.

Raiz Invest reported robust Q4 FY26 growth with active customers climbing 6.7% and funds under management hitting $2.32 billion, while confirming FY26 profitability guidance.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

Cauldron Energy’s latest passive seismic survey reveals the Manyingee palaeochannel extends further northwest into its tenements, spotlighting new uranium mineralisation potential at Yanrey.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

McLaren Minerals’ 2026 drilling at its Western Australia titanium project delivers broad, repeatable heavy mineral grades averaging 3.76% over 21 metres from surface, reinforcing resource continuity and advancing feasibility plans.

Connected Minerals has secured shareholder and regulatory approvals to acquire Frontier Group, gaining an 80% stake in Angola’s Bailundo Carbonatite Project with expanded mineral rights including niobium and rare earths. Completion is imminent as exploration activities ramp up.

Anson Resources has dramatically expanded its Green River Lithium Project resource and confirmed robust project economics, while sealing a key agreement with POSCO for a demonstration plant funded by the Korean industrial giant.

Oceana Metals has validated extensive high-grade rare earth mineralisation at its Serra Negra project in Brazil, underpinning a major drilling campaign backed by a $20 million capital raise.